Clinical and experimental studies with oral aluminum hydroxide.
Experimental studies in 10 paraplegic patients showed highly significant reduction in urinary saturation associated with the oral administration of aluminium hydroxide. Only 50 per cent of urine samples from five patients with calculous disease were actually undersaturated, however. During clinical studies in 12 patients with renal calculous disease, four had recurrence or growth of calculi while receiving medication, three had no recurrence during therapy, but new stones appeared after the medication was stopped, and five had no growth or recurrence either during therapy or after its cessation.
D000284:Administration, Oral; D000328:Adult; D000536:Aluminum Hydroxide / Q000627:therapeutic use* / Q000652:urine; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010264:Paraplegia / Q000150:complications* / Q000652:urine; D012008:Recurrence
D000536:Aluminum Hydroxide